JP2007537147A5 - - Google Patents

Download PDF

Info

Publication number
JP2007537147A5
JP2007537147A5 JP2006547452A JP2006547452A JP2007537147A5 JP 2007537147 A5 JP2007537147 A5 JP 2007537147A5 JP 2006547452 A JP2006547452 A JP 2006547452A JP 2006547452 A JP2006547452 A JP 2006547452A JP 2007537147 A5 JP2007537147 A5 JP 2007537147A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
composition
unsubstituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006547452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007537147A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/043586 external-priority patent/WO2005066197A2/en
Publication of JP2007537147A publication Critical patent/JP2007537147A/ja
Publication of JP2007537147A5 publication Critical patent/JP2007537147A5/ja
Pending legal-status Critical Current

Links

JP2006547452A 2003-12-29 2004-12-29 メチオニンアミノペプチダーゼ−2のインヒビターおよびその使用 Pending JP2007537147A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53343103P 2003-12-29 2003-12-29
PCT/US2004/043586 WO2005066197A2 (en) 2003-12-29 2004-12-29 Inhibitors of methionine aminopeptidase-2 and uses thereof

Publications (2)

Publication Number Publication Date
JP2007537147A JP2007537147A (ja) 2007-12-20
JP2007537147A5 true JP2007537147A5 (enExample) 2008-02-07

Family

ID=34748901

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006547452A Pending JP2007537147A (ja) 2003-12-29 2004-12-29 メチオニンアミノペプチダーゼ−2のインヒビターおよびその使用

Country Status (9)

Country Link
US (1) US20050239878A1 (enExample)
EP (1) EP1699812A2 (enExample)
JP (1) JP2007537147A (enExample)
KR (1) KR20060130077A (enExample)
CN (1) CN1902215A (enExample)
AU (1) AU2004312512A1 (enExample)
CA (1) CA2550873A1 (enExample)
NO (1) NO20062812L (enExample)
WO (1) WO2005066197A2 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
JP4514455B2 (ja) * 2002-04-11 2010-07-28 チルドレンズ メディカル センター コーポレーション Tnp−470ポリマー複合体及びその使用
WO2007124005A2 (en) * 2006-04-18 2007-11-01 Praecis Pharmaceuticals Incorporated Methods for treating bone associated diseases by the use of methionine aminopeptidase-2 inhibitors
WO2008066641A2 (en) * 2006-11-06 2008-06-05 Praecis Pharmaceuticals Incorporated Methods for treating mitf associated diseases by the use of methionine aminopeptidase-2 inhibitors
JP2010531896A (ja) * 2007-06-26 2010-09-30 チルドレンズ メディカル センター コーポレーション 治療的投与のためのMetAP−2阻害剤ポリマーソーム
EP2317845A4 (en) * 2008-07-18 2011-11-09 Zafgen Inc METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
BR112012016793A2 (pt) 2010-01-08 2018-07-31 Zafgen Corp compostos tipo fumagilol e métodos de fazer e usar os mesmos
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
US20130316994A1 (en) 2010-11-29 2013-11-28 Zafgen, Inc. Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン,インコーポレイテッド 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
AU2012225531B2 (en) 2011-03-08 2017-03-30 Zafgen, Inc Oxaspiro (2.5) octane derivatives and analogs
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
BR112014027808A2 (pt) 2012-05-07 2017-06-27 Zafgen Inc sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo
EP2846792B1 (en) 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
CN104364251B (zh) 2012-05-09 2017-02-22 扎夫根股份有限公司 烟曲霉醇型化合物及其制备和使用方法
CN104918928A (zh) 2012-11-05 2015-09-16 扎夫根股份有限公司 三环化合物及其制备方法和用途
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
KR20150126924A (ko) 2013-03-14 2015-11-13 자프겐 인크. 신장 질환 및 기타 장애의 치료 방법
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
US20200030278A1 (en) * 2017-02-10 2020-01-30 Zafgen, Inc. Pharmaceutical compositions of metap-2 inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
US5135919A (en) * 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
EP0359036B1 (en) * 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Fumagillol derivatives
US5180738A (en) * 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US6017954A (en) * 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法
ATE153854T1 (de) * 1992-12-16 1997-06-15 Takeda Chemical Industries Ltd Stabile pharmazeutische zubereitung mit fumagillolderivaten
FR2733498B1 (fr) * 1995-04-27 1997-05-30 Adir Nouveaux composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis

Similar Documents

Publication Publication Date Title
JP2006505543A5 (enExample)
JP2003508388A5 (enExample)
JP2020169171A5 (enExample)
JP2006514012A5 (enExample)
JP2009536660A5 (enExample)
JP2012508252A5 (enExample)
RU2007116119A (ru) Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с
JP2005523922A5 (enExample)
JP2023524821A5 (enExample)
JP2004503564A5 (enExample)
JP2010504908A5 (enExample)
JP2008535902A5 (enExample)
GB0428082D0 (en) Therapeutic compounds
JP2004534850A5 (enExample)
CA2518115A1 (en) Nucleotide phosphoramidates as anticancer agents
RU2007123235A (ru) Противоопухолевые соединения
JP2020097577A5 (enExample)
JP2012504133A5 (enExample)
RU2008119692A (ru) Новые 1-азабициклоалкилпроизводные для лечения психических растройств
RU2013146659A (ru) Способы лечения рака
JP2006504753A5 (enExample)
JP2004502755A5 (enExample)
JP2010513285A5 (enExample)
JP2009520695A5 (enExample)
JP2012518649A5 (enExample)